

Journal Article



Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain

Journal	Cancer Immunology, Immunotherapy
Publisher	Springer Berlin / Heidelberg
ISSN	0340-7004 (Print) 1432-0851 (Online)
Status	ONLINE FIRST
Category	Original Article
DOI	10.1007/s00262-008-0461-1
Subject Collection	Biomedical and Life Sciences
SpringerLink Date	Wednesday, February 06, 2008

Robert M. Prins^{1, 2, 3, 4} ✉, Chengyi J. Shu⁵, Caius G. Radu^{3, 5}, Dan D. Vo⁶, Haumith Khan-Farooqi¹, Horacio Soto¹, Meng-Yin Yang¹, Muh-Shi Lin¹, Stephanie Shelly⁵, Owen N. Witte^{2, 3, 5, 7}, Antoni Ribas^{3, 6, 8} and Linda M. Liau^{1, 3, 4}

- (1) Department of Surgery, Division of Neurosurgery, David Geffen School of Medicine at UCLA, CHS 74-145, 10833 Le Conte Avenue, PO Box 956901, Los Angeles, CA 90095, USA
- (2) Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
- (3) Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
- (4) Brain Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
- (5) Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
- (6) Department of Surgery, Division of Surgical Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
- (7) Howard Hughes Medical Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
- (8) Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Received: 23 November 2007 **Accepted:** 15 January 2008 **Published online:** 6 February 2008

Abstract It is commonly believed that T cells have difficulty reaching tumors located in the brain due to the presumed "immune privilege" of the central nervous system (CNS). Therefore, we studied the biodistribution and anti-tumor activity of adoptively transferred T cells specific for an endogenous tumor-associated antigen (TAA), gp100, expressed by tumors implanted in the brain. Mice with pre-established intracranial (i.c.) tumors underwent total body irradiation (TBI) to induce transient lymphopenia, followed by the adoptive transfer of gp100₂₅₋₃₃-specific CD8⁺ T cells (Pmel-1). Pmel-1 cells were transduced to express the bioluminescent imaging (BLI) gene luciferase. Following adoptive transfer, recipient mice were vaccinated with hgp100₂₅₋₃₃ peptide-pulsed dendritic cells (hgp100₂₅₋₃₃/DC) and systemic interleukin 2 (IL-2). This treatment regimen resulted in significant reduction in tumor size and extended survival. Imaging of T cell trafficking demonstrated early accumulation of transduced T

cells in lymph nodes draining the hgp100₂₅₋₃₃/DC vaccination sites, the spleen and the cervical lymph nodes draining the CNS tumor. Subsequently, transduced T cells accumulated in the bone marrow and brain tumor. BLI could also detect significant differences in the expansion of gp100-specific CD8⁺ T cells in the treatment group compared with mice that did not receive either DC vaccination or IL-2. These differences in BLI correlated with the differences seen both in survival and tumor infiltrating lymphocytes (TIL). These studies demonstrate that peripheral tolerance to endogenous TAA can be overcome to treat tumors in the brain and suggest a novel trafficking paradigm for the homing of tumor-specific T cells that target CNS tumors.

Electronic supplementary material The online version of this article (doi:10.1007/s00262-008-0461-1) contains supplementary material, which is available to authorized users.

Keywords Brain tumor - Immunotherapy - T cell trafficking - Dendritic cells

✉ **Robert M. Prins**
Email: rprins@mednet.ucla.edu

References secured to subscribers.

Copyright ©2008, Springer. All Rights Reserved.